{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:16:42Z","timestamp":1784013402620,"version":"3.55.0"},"reference-count":91,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized collectively by clonal proliferation of myeloid cells with variable morphologic maturity and hematopoietic efficiency. Although the natural history of these neoplasms can be measured sometimes in decades more than years, the cytogenetics analysis can offer useful information regarding the prognosis. Cytogenetics has a well-established prognostic role in acute leukemias and in myelodysplastic syndromes, where it drives the clinical decisions. NGS techniques can find adverse mutations with clear prognostic value and are currently included in the prognostic evaluation of MPNs in scores such as MIPSS, GIPSS, MIPSS-PV, and MIPSS-ET. We suggest that cytogenetics (considering its availability and relative cost) has a role regarding prognostic and therapeutic decisions.<\/jats:p>","DOI":"10.3390\/medicina57080813","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T09:03:53Z","timestamp":1628499833000},"page":"813","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-0798","authenticated-orcid":false,"given":"Giuseppe","family":"Lanzarone","sequence":"first","affiliation":[{"name":"Unit of Hematology, Department of Oncology, University of Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Olivi","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Department of Oncology, University of Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2V617F mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","first-page":"22.1.1","article-title":"Overview of Cytogenetic Chromosome Analysis","volume":"23","author":"Bayani","year":"2004","journal-title":"Curr. Protoc. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2009-07-235119","article-title":"Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"115","author":"Thoennissen","year":"2010","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative Neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with Myeloid Metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/leu.2014.250","article-title":"Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: Consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)","volume":"29","author":"Barosi","year":"2015","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders","volume":"22","author":"Cervantes","year":"2008","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International Prognostic Scoring System\u2013independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","article-title":"Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients","volume":"25","author":"Caramazza","year":"2010","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2011-08-371096","article-title":"Predictors of greater than 80% 2-year mortality in primary myelofibrosis: A Mayo Clinic study of 884 karyotypically annotated patients","volume":"118","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/leu.2008.218","article-title":"Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs)","volume":"22","author":"Reilly","year":"2008","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2009.01224.x","article-title":"Conventional cytogenetics in myelofibrosis: Literature review and discussion","volume":"82","author":"Hussein","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0609.2009.01216.x","article-title":"Karyotype complements the International Prognostic Scoring System for primary myelofibrosis","volume":"82","author":"Hussein","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2141.1997.1722990.x","article-title":"Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: A study of 106 cases","volume":"98","author":"Reilly","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cancergencyto.2006.09.021","article-title":"Cytogenetics of agnogenic myeloid metaplasia: A study of 61 patients","volume":"173","author":"Jovanovic","year":"2007","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood.V72.3.855.bloodjournal723855","article-title":"Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: A report on 47 cases","volume":"72","author":"Demory","year":"1988","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/1097-0142(19850201)55:3<582::AID-CNCR2820550318>3.0.CO;2-O","article-title":"The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis","volume":"55","author":"Miller","year":"1985","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0165-4608(87)90092-6","article-title":"Cytogenetic studies in twelve patients with primary myelofibrosis and myeloid metaplasia","volume":"24","author":"Smadja","year":"1987","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1600-0609.2009.01298.x","article-title":"The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: A prospective survey of 202 cases in Japan","volume":"83","author":"Hidaka","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2008-09-178541","article-title":"The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS","volume":"96","author":"Elena","year":"2010","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","article-title":"Revised cytogenetic risk stratification in primary myelofibrosis: Analysis based on 1002 informative patients","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0165-4608(02)00678-7","article-title":"Karyotypic abnormalities in myelofibrosis following polycythemia vera","volume":"140","author":"Andrieux","year":"2003","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.21868","article-title":"Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis","volume":"106","author":"Dingli","year":"2006","journal-title":"Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/leu.2017.297","article-title":"Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis","volume":"32","author":"Pereira","year":"2018","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.seminhematol.2018.05.013","article-title":"Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and\/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study","volume":"55","author":"Palandri","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1600-0609.2007.01003.x","article-title":"Cytogenetic studies at diagnosis in polycythemia vera: Clinical and JAK2V617F allele burden correlates","volume":"80","author":"Gangat","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V72.2.386.386","article-title":"A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course","volume":"72","author":"Swolin","year":"1988","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjh.14798","article-title":"Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance","volume":"182","author":"Barraco","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3109\/10428194.2013.784970","article-title":"Significance of cytogenetic abnormalities in patients with polycythemia vera","volume":"54","author":"Sever","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0025-6196(12)61011-8","article-title":"Chromosome Studies in 104 Patients With Polycythemia Vera","volume":"66","author":"Graham","year":"1991","journal-title":"Mayo Clin. Proc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0308-2261(21)00168-5","article-title":"Cytogenetic studies in Philadelphia chromosome-negative myeloproliferative disorders, particularly polycythaemia rubra vera","volume":"9","author":"Lawler","year":"1980","journal-title":"Clin. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2017.165795","article-title":"Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera","volume":"102","author":"Tang","year":"2017","journal-title":"Haematologica"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative Neoplasms","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ajh.24338","article-title":"Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia","volume":"91","author":"Elala","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"E128","DOI":"10.1002\/ajh.25065","article-title":"Mayo CALR mutation type classification guide using alpha helix propensity","volume":"93","author":"Lasho","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0159-3","article-title":"MPL-mutated essential thrombocythemia: A morphologic reappraisal","volume":"8","author":"Szuber","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Feenstra","year":"2016","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00277-004-0977-1","article-title":"Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information","volume":"84","author":"Bacher","year":"2005","journal-title":"Ann. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-0609.2009.01246.x","article-title":"Cytogenetic abnormalities in essential thrombocythemia: Prevalence and prognostic significance","volume":"83","author":"Gangat","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.leukres.2005.03.011","article-title":"De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia","volume":"29","author":"Hsiao","year":"2005","journal-title":"Leuk. Res."},{"key":"ref_64","first-page":"381","article-title":"Cytogenetic findings in untreated patients with essential thrombocythemia","volume":"20","author":"Panani","year":"2006","journal-title":"In Vivo"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0165-4608(89)90127-1","article-title":"Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation: A 12-year study","volume":"43","author":"Sessarego","year":"1989","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12185-009-0411-5","article-title":"Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation","volume":"90","author":"Sever","year":"2009","journal-title":"Int. J. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0950-3536(98)80041-3","article-title":"7 Molecular genetics and cytogenetics of myeloproliferative disorders","volume":"11","author":"Bench","year":"1998","journal-title":"Bailli\u00e8re\u2019s Clin. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2007.02.009","article-title":"Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: Clinical implications","volume":"255","author":"Panani","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/jclinpath-2015-203060","article-title":"Chronic neutrophilic leukaemia","volume":"68","author":"Uppal","year":"2015","journal-title":"J. Clin. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2141.2002.03234.x","article-title":"Chronic neutrophilic leukaemia: A distinct clinical entity?","volume":"116","author":"Reilly","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000205548","article-title":"A Case of Chronic Neutrophilic Leukemia with Trisomy 8","volume":"81","author":"Orazi","year":"1989","journal-title":"Acta Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1046\/j.1365-2141.1996.7082329.x","article-title":"Chronic neutrophil leukaemia in adolescence and young adulthood","volume":"94","author":"Hasle","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0165-4608(98)00177-0","article-title":"A Case of Chronic Neutrophilic Leukemia with Deletion (11)(q23)","volume":"110","author":"Garcia","year":"1999","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-8652(199701)54:1<72::AID-AJH11>3.0.CO;2-C","article-title":"Deletion of the long arm of chromosome 20 in a patient with chronic neutrophilic leukemia: Cytogenetic findings in chronic neutrophilic leukemia","volume":"54","author":"Matano","year":"1997","journal-title":"Am. J. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3324\/haematol.2017.165340","article-title":"Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2141.1999.01458.x","article-title":"Systemic mastocytosis and other mast cell neoplasms","volume":"106","author":"Bain","year":"1999","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0091-6749(96)70243-9","article-title":"Trisomies 9 and 8 detected by fluorescence in situ hybridization in patients with systemic mastocytosis","volume":"98","author":"Lishner","year":"1996","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V70.6.1928.1928","article-title":"Cytogenetic studies and in vitro colony growth in patients with mastocytosis","volume":"70","author":"Swolin","year":"1987","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0165-4608(99)00256-3","article-title":"Cytogenetic Studies in Patients with Mastocytosis","volume":"120","author":"Swolin","year":"2000","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/gcc.22526","article-title":"Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis","volume":"57","author":"Naumann","year":"2018","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/ajh.25265","article-title":"Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases","volume":"93","author":"Shah","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_83","first-page":"31","article-title":"The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features","volume":"65","author":"Borovecki","year":"2011","journal-title":"Acta Med. Croat."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.leukres.2008.04.022","article-title":"Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): Clinicopathologic comparison of del(5q)-positive and -negative cases","volume":"32","author":"Tefferi","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/ijlh.12257","article-title":"Genomic aberrations of myeloproliferative and myelodysplastic\/myeloproliferative neoplasms in chronic phase and during disease progression","volume":"37","author":"Hahm","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/252537","article-title":"Transformation of an Unclassified Myeloproliferative Neoplasm with a RareBCR-JAK2Fusion Transcript Resulting from the Translocation (9;22)(p24;q11)","volume":"2015","author":"Chamseddine","year":"2015","journal-title":"Case Rep. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0268-960X(03)00040-7","article-title":"Cytogenetics in acute leukemia","volume":"18","author":"Heerema","year":"2004","journal-title":"Blood Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/archdischild-2013-304340","article-title":"What is next generation sequencing?","volume":"98","author":"Behjati","year":"2013","journal-title":"Arch. Dis. Child. Educ. Pr. Ed."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/0008-5472.CAN-12-0735","article-title":"Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms","volume":"73","author":"Nischal","year":"2013","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cancergen.2017.07.010","article-title":"Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies","volume":"216\u2013217","author":"Mukherjee","year":"2017","journal-title":"Cancer Genet."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/8\/813\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:42:58Z","timestamp":1760164978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/8\/813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":91,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["medicina57080813"],"URL":"https:\/\/doi.org\/10.3390\/medicina57080813","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,9]]}}}